Physician profile
Jin Sung Lee
NPI 1891766721
$9,781.47
in general payments reported to CMS, 2019-2025
61 companies · $616 in 2025
The $616 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $3,037 · 2021: $868 · 2022: $2,862 · 2023: $953 · 2024: $925 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.56 |
| Education | $280.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,193.63 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Rigel Pharmaceuticals, INC. | $1,505.24 | 2021-2022 | |
| Janssen Biotech, INC. | $525.33 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $479.60 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $438.93 | 2019-2024 | |
| Abbvie INC. | $400.38 | 2022-2025 | |
| Daiichi Sankyo INC. | $245.41 | 2020-2025 | Datroway, Enhertu, Injectafer |
| Aveo Pharmaceuticals, INC. | $234.26 | 2024-2025 | |
| Amgen INC. | $184.21 | 2019-2023 | Lumakras |
| Morphosys, US INC. | $152.94 | 2021 | |
| Seagen INC. | $144.83 | 2022-2023 | Padcev |
| Genentech USA, INC. | $134.16 | 2021-2025 | Venclexta, Tecentriq, Gazyva |
| Pfizer INC. | $132.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $131.85 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $130.95 | 2021-2024 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Sung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.